Nyxoah S.A. (NASDAQ:NYXH) Sees Significant Drop in Short Interest

Nyxoah S.A. (NASDAQ:NYXH) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 63,700 shares, a decrease of 36.4% from the February 28th total of 100,200 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is currently 1.3 days.

Wall Street Analyst Weigh In

NYXH has been the subject of several recent research reports. Stifel Nicolaus reduced their price target on Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 14th. HC Wainwright lowered their price target on shares of Nyxoah from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday.

Nyxoah Price Performance

Shares of NASDAQ:NYXH traded down $0.35 during trading on Friday, reaching $7.65. 81,348 shares of the company traded hands, compared to its average volume of 46,675. The firm has a market capitalization of $260.56 million, a PE ratio of -4.09 and a beta of 1.42. Nyxoah has a 52 week low of $6.76 and a 52 week high of $13.50. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $10.35 and its two-hundred day moving average is $9.36.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. As a group, sell-side analysts predict that Nyxoah will post -1.91 earnings per share for the current year.

Institutional Trading of Nyxoah

Several large investors have recently made changes to their positions in the company. Vestal Point Capital LP bought a new stake in Nyxoah during the fourth quarter worth $23,394,000. Ameriprise Financial Inc. acquired a new position in shares of Nyxoah during the 4th quarter worth $135,000. Walleye Capital LLC lifted its position in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock worth $119,000 after buying an additional 2,862 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Nyxoah in the fourth quarter valued at about $187,000. Finally, Geode Capital Management LLC grew its position in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after acquiring an additional 2,774 shares during the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.